bempedoic acid Cancer Research Results

bemA, bempedoic acid: Click to Expand ⟱
Features:

Bempedoic acid — Bempedoic acid is a synthetic, orally administered small-molecule prodrug that is converted by very long-chain acyl-CoA synthetase 1 (ACSVL1/SLC27A2) to an active CoA thioester that inhibits ATP-citrate lyase (ACLY), thereby reducing cytosolic acetyl-CoA supply for cholesterol synthesis and de novo lipogenesis. It is formally classified as an approved lipid-lowering drug and first-in-class ACLY inhibitor; standard abbreviations include BA and BemA. Its established clinical use is cardiovascular/metabolic rather than oncologic, and its cancer relevance is currently mechanistic/preclinical, centered on tumor lipid-metabolism dependence and context-dependent immune effects. Bempedoic acid (ETC-1002) is a small molecule intended to lower LDL-C in hypercholesterolemic patients

Primary mechanisms (ranked):

  1. ACLY inhibition with reduced cytosolic acetyl-CoA generation, lowering sterol and fatty-acid biosynthetic flux.
  2. Suppression of de novo lipogenesis and membrane-building/anabolic support required by proliferating cancer cells.
  3. Downstream growth inhibition and apoptosis in some tumor models, including reduced invasion in selected breast and pancreatic cell systems.
  4. Immune-context modulation: ACLY inhibition can increase PUFA peroxidation, mitochondrial stress, cGAS-STING signaling, and PD-L1 expression, which may either hinder monotherapy efficacy or create combination opportunities with checkpoint blockade depending on model context.
  5. Secondary hepatocyte-linked AMPK/ACC modulation has been reported, but this is not yet the most reliable cancer-facing primary axis.

Bioavailability / PK relevance: Oral once-daily drug; FDA labeling states median Tmax is about 3.5 hours, food does not meaningfully affect oral bioavailability, plasma protein binding is very high (~99.3%), and mean half-life is about 21 hours. A key delivery constraint is biologic activation: bempedoic acid requires ACSVL1-mediated CoA conversion, with activation primarily in liver and limited activity expected in tissues lacking that enzyme, so tumor responsiveness is likely expression-context dependent rather than simply dose dependent.

In-vitro vs systemic exposure relevance: Many mechanistic oncology studies use about 25–30 µM. Reported human total Cmax is in the same broad range, but the drug is highly protein bound and antitumor activity additionally depends on cellular activation to bempedoyl-CoA, so nominal in-vitro concentrations can overstate broadly achievable free/active exposure in tumors. This is therefore not a clean “plasma concentration equals tumor effect” agent.

Clinical evidence status: Approved drug with strong cardiovascular RCT evidence, but cancer evidence remains preclinical and combination-hypothesis generating. No established oncology indication and no clear oncology trial program was identified in current major registry searches.

Mechanistic profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ACLY and cytosolic acetyl-CoA supply ↓ ↓ (tissue-dependent) R-G Restrains anabolic carbon flow into cholesterol and fatty-acid synthesis Core validated target of the drug. Cancer relevance is strongest in tumors dependent on lipogenic flux and able to activate the prodrug.
2 De novo lipogenesis ↓ ↓ G Reduces membrane lipid supply and metabolic support for proliferation Mechanistically central downstream consequence of ACLY inhibition; likely more relevant than isolated cholesterol effects in many tumors.
3 Cell proliferation and survival ↓ proliferation; ↑ apoptosis (model-dependent) ↔ / milder effect G Growth suppression with apoptosis in selected models Supported in breast and pancreatic cell systems, especially in combination settings; not yet generalized across tumor types.
4 Invasion and metastatic behavior ↓ ↔ G Reduces invasive phenotype Observed in transwell/in vitro systems with ACLY inhibition; plausibly linked to altered lipid availability and signaling.
5 Mitochondrial damage and lipid peroxidation ↑ (context-dependent) ↔ / unclear R-G Can trigger stress signaling after ACLY blockade In immunology-focused tumor work, ACLY inhibition promoted PUFA peroxidation and mitochondrial DNA leakage rather than acting as a simple purely cytostatic metabolic block.
6 cGAS-STING innate sensing ↑ (context-dependent) ↔ R-G Activates innate stress signaling This axis may be double-edged: it can support combination immunotherapy logic, yet also induce adaptive immune escape programs.
7 PD-L1 and T-cell dysfunction axis ↑ PD-L1 Immune cells: indirect dysfunction in vivo G Potential immunosuppressive compensation Important translational caution: ACLY inhibition can blunt antitumor benefit in immunocompetent settings if used alone.
8 AMPK and ACC modulation ↑ / ↓ lipogenesis (secondary, context-dependent) ↑ in hepatocyte-dominant settings R-G Secondary metabolic reinforcement Reported in liver-focused studies and reviews, but less secure as the primary cancer-facing mechanism than direct ACLY blockade.
9 Clinical Translation Constraint Activation-limited; no oncology validation Liver-selective activation helps tolerability G Restricts direct anticancer translation Major constraints are very high protein binding, requirement for ACSVL1/SLC27A2 activation, uncertain tumor penetration/activation, hyperuricemia and tendon-rupture warnings, statin interaction constraints, and absence of oncology trials.
P: 0–30 min
R: 30 min–3 hr
G: >3 hr
Scientific Papers found: Click to Expand⟱
5509- bemA,    Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
- Review, Nor, NA
LDL↓, AMPK↑, ACLY↓,
5510- bemA,    Combined inhibition of ACLY and CDK4/6 reduces cancer cell growth and invasion
- in-vitro, BC, MDA-MB-231 - in-vitro, PC, NA
eff↑, Apoptosis↑, TumCI↓, ACLY↓, LDL↓, eff↑, TumCP↓,
5511- bemA,    Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation
- in-vitro, Var, NA
ACLY↓, PD-L1↑, mtDam↑, cGAS–STING↑, LDL↓, eff↑,
5512- bemA,    Recent advance of ATP citrate lyase inhibitors for the treatment of cancer and related diseases
- Review, Var, NA
ACLY↓, other↝, CSCs↓,
5513- bemA,    ACLY inhibition promotes tumour immunity and suppresses liver cancer
- in-vitro, Liver, NA
ACLY↓, AMPK↑, eff↑, other↝, eff↝,
5514- bemA,    Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
- Trial, Nor, NA
*ACLY↓, *LDL↓, *MusCon↓, Dose↝, cardioP↑,

Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics ⓘ

mtDam↑, 1,  

Core Metabolism/Glycolysis ⓘ

ACLY↓, 5,   AMPK↑, 2,   LDL↓, 3,  

Cell Death ⓘ

Apoptosis↑, 1,  

Transcription & Epigenetics ⓘ

other↝, 2,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 1,  

Migration ⓘ

TumCI↓, 1,   TumCP↓, 1,  

Immune & Inflammatory Signaling ⓘ

PD-L1↑, 1,  

Cellular Microenvironment ⓘ

cGAS–STING↑, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,   eff↑, 4,   eff↝, 1,  

Clinical Biomarkers ⓘ

PD-L1↑, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,  
Total Targets: 16

Pathway results for Effect on Normal Cells:


Core Metabolism/Glycolysis ⓘ

ACLY↓, 1,   LDL↓, 1,  

Functional Outcomes ⓘ

MusCon↓, 1,  
Total Targets: 3

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:63  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page